HC Wainwright Issues Optimistic Estimate for DTIL Earnings

Key Points

• HC Wainwright analysts have raised their Q3 2025 earnings per share estimate for Precision BioSciences to ($0.31), up from a previous estimate of ($0.38), while maintaining a "Buy" rating with a target price of $60.00.
• Precision BioSciences reported a significantly higher loss of ($2.13) EPS for the latest quarter, which was far below the analysts' consensus estimate of ($0.09).
• Insider trading activity indicates that CFO John Alexander Kelly sold nearly 15,000 shares, decreasing his ownership by 16.79%, amid a backdrop of varied institutional investment strategies in the company's stock.

Precision BioSciences, Inc. (NASDAQ:DTIL - Free Report) - Equities research analysts at HC Wainwright upped their Q3 2025 EPS estimates for Precision BioSciences in a research note issued on Monday, August 11th. HC Wainwright analyst P. Trucchio now anticipates that the company will earn ($0.31) per share for the quarter, up from their prior forecast of ($0.38). HC Wainwright has a "Buy" rating and a $60.00 price objective on the stock. The consensus estimate for Precision BioSciences' current full-year earnings is ($1.23) per share. HC Wainwright also issued estimates for Precision BioSciences' FY2025 earnings at ($4.57) EPS, Q1 2026 earnings at ($0.16) EPS, Q2 2026 earnings at ($0.16) EPS, Q3 2026 earnings at ($0.16) EPS, Q4 2026 earnings at $0.94 EPS, FY2026 earnings at $0.47 EPS, FY2027 earnings at $0.93 EPS, FY2028 earnings at $1.15 EPS and FY2029 earnings at $0.15 EPS.

Precision BioSciences (NASDAQ:DTIL - Get Free Report) last posted its earnings results on Thursday, August 7th. The company reported ($2.13) EPS for the quarter, missing analysts' consensus estimates of ($0.09) by ($2.04). Precision BioSciences had a negative net margin of 6,205.79% and a negative return on equity of 176.47%. The company had revenue of $0.02 million during the quarter, compared to analyst estimates of $6.27 million.

Precision BioSciences Trading Down 2.4%

NASDAQ:DTIL traded down $0.12 on Thursday, reaching $4.83. 17,882 shares of the company's stock were exchanged, compared to its average volume of 330,271. The company has a quick ratio of 5.18, a current ratio of 5.18 and a debt-to-equity ratio of 0.66. The firm has a market capitalization of $56.95 million, a price-to-earnings ratio of -0.55 and a beta of 1.52. The business has a fifty day moving average of $4.67 and a 200-day moving average of $4.92. Precision BioSciences has a 52-week low of $3.61 and a 52-week high of $11.09.

Hedge Funds Weigh In On Precision BioSciences

A number of institutional investors and hedge funds have recently made changes to their positions in DTIL. Miller Financial Services LLC acquired a new position in shares of Precision BioSciences during the first quarter worth about $48,000. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its position in shares of Precision BioSciences by 22.0% during the fourth quarter. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 15,534 shares of the company's stock worth $59,000 after buying an additional 2,805 shares in the last quarter. XTX Topco Ltd acquired a new position in shares of Precision BioSciences during the fourth quarter worth about $67,000. Jane Street Group LLC acquired a new position in shares of Precision BioSciences during the fourth quarter worth about $146,000. Finally, Squarepoint Ops LLC acquired a new position in shares of Precision BioSciences during the fourth quarter worth about $179,000. 37.99% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Precision BioSciences

In other Precision BioSciences news, CFO John Alexander Kelly sold 14,827 shares of the business's stock in a transaction dated Thursday, July 3rd. The shares were sold at an average price of $4.26, for a total transaction of $63,163.02. Following the sale, the chief financial officer directly owned 73,485 shares in the company, valued at $313,046.10. This represents a 16.79% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 4.00% of the stock is owned by company insiders.

About Precision BioSciences

Precision BioSciences, Inc, an advanced gene editing company, develops in vivo gene editing therapies for gene edits, including gene elimination, insertion, and excision in the United States. The company offers ARCUS, a genome editing platform to DNA genome insertion, deletion, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; PBGENE-PMM for the treatment of m.3243 associated primary mitochondrial myopathy (PMM) which is expected to submit an IND and/or CTA.